Inhibits both Gli1/2 downstream effectors to decrease tumor growth. ATO is FDA approved to treat leukemia. Other inhibitors in this category are under preclinical testing for prostate, colon, and ovarian cancers. This evidence concerns the gene GLI1 and ovarian carcinoma.